European Journal of Obstetrics & Gynecology and Reproductive Biology
ReviewCorrection of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes
Section snippets
Introduction: clomiphene resistance defined
While a formal classification system for PCOS patient response following clomiphene therapy has not been developed, a thorough review of a patient’s prior clomiphene treatment outcomes is needed to recognize ineffective therapy. Ovulation induction with clomiphene has been extensively studied; clinical experience has demonstrated this agent will elicit a safe, ovulatory response in an impressive proportion of women who use it [1]. Importantly, over 80% of women who successfully achieve a
Initial evaluation
After a thorough history and focused physical examination (including transvaginal ultrasound assessment of ovaries and endometrium), objective laboratory evidence supporting hyperandrogenism and/or hyperinsulinemia should be sought. PCOS patients should undergo endometrial biopsy whenever endometrial hyperplasia is suggested by transvaginal sonography. When present, hirsutism, acanthosis nigricans and obesity should be recorded.
Helpful laboratory tests include fasting insulin and glucose,
Metformin as a normogonadotropin in gynecology practice
Like clomiphene, metformin is a nonsteroidal compound that indirectly influences ovarian function. Metformin is a water soluable, oral biguanide insulin-lowering drug; it is chemically and pharmacologically distinct from sulfonylureas (see Fig. 1). Metformin results in blunting of hepatic gluconeogenesis, diminished intestinal absorption of glucose, and increased peripheral glucose uptake and utilization [10]. In contrast to the physiological response to sulfonylureas, metformin does not modify
Metformin precautions and patient counseling
All women receiving metformin therapy for PCOS should be thoroughly briefed about the risk of lactic acidosis associated with this medication. Lactic acidosis is a rare (1:33 000) metabolic complication of metformin therapy, thought to be secondary to significant tissue hypoxia [16]. When lactic acidosis occurs it is a medical emergency; the case fatality rate is 50%. Such risk calculations were extrapolated from diabetic study populations prior to marketing the drug specifically for diabetes
Metformin dosing and monitoring
Metformin therapy for ovulation induction in PCOS generally commences in the early follicular phase, but since most PCOS women are acyclic this guideline is of little clinical value. Induction of menses following progestational challenge should be considered when endometrial thickness is extreme (>10 mm), but routine pre-treatment with progestins in the setting of PCOS is probably unnecessary.
A supervised, incremental dosage protocol is used to administer metformin to PCOS patients at this
Clinical results
During the initial month of metformin treatment, often no appreciable impact on the BBT characteristics compared to pre-treatment controls is evident (see Fig. 3a). The disorganized, monophasic pattern associated with oligoovulatory or anovulatory cycles occasionally persists through the first 4–6 weeks of metfomin therapy. At this center, prolonged latency of non-biphasic BBT patterns has been observed more commonly among heavier (BMI >32) patients who have failed to implement a structured
Ovulatory response and conception following metformin
Evidence supporting ovarian responsiveness to metformin has accumulated from several institutions through small studies published during the past decade. For example, among 22 PCOS patients receiving metformin at a Venezuelan center, all but one achieved normal menstrual cyclicity within six months [20]. In this group, healthy infants were delivered from four study patients who conceived spontaneously within the first seven months of metformin therapy. Similarly, a study of 15 adolescents with
Conclusion
At present, mainstream clinical opinion still regards clomiphene as the first-line strategy to induce ovulation in patients with PCOS. Any associated insulin/glucose dysfunction of PCOS remains uncorrected with this regimen, however. Fasting insulin levels may be inversely related to the ovulatory response manifested by clomiphene in some women. Beneficial metabolic effects of insulin reduction among PCOS patients seem to include improved menstrual regularity and fertility. Several small
Condensation
Restoration of normal insulin homeostasis should be a prime clinical objective in the management of polycystic ovary syndrome.
Acknowledgements
The authors are grateful to Dr. Delphine P.Levy for review of this manuscript, and to the clinical and scientific staffs at Georgia Reproductive Specialists LLC, and The Center For Reproductive Medicine & Infertility, Weill Medical College of Cornell University for technical and research support.
References (33)
- et al.
A decade’s experience with an individualized clomiphene treatment regimen including its effect on the postcoital test
Fertil Steril
(1982) - et al.
The importance of endogenous feedback for monofollicular growth in low-dose step-up ovulation induction with follicle stimulating hormone in polycystic ovary syndrome: a randomized study
Fertil Steril
(1996) - et al.
Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin
Fertil Steril
(1993) - et al.
Insulin as an effector of human ovarian and adrenal steroid metabolism
Endocrinol Metab Clin North Am
(1991) Lactic acidosis
Am J Cardiol
(1963)- et al.
Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome
Metabolism
(1999) Polycystic ovary syndrome: induction of ovulation
Ballieres Clin Endocrinol Metab
(1996)- et al.
Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome
Metabolism
(1997) - et al.
The plasminogen activator system in women with polycystic ovary syndrome
Fertil Steril
(1998) - et al.
Induction of ovulation with MRL/41
J Am Med Assoc
(1962)
Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease
J Clin Endocrinol Metab
Polycystic ovary syndrome: a new direction in treatment
Med J Aust
The number of follicles and ovarian volume in the assessment of response to clomiphene citrate treatment in polycystic ovarian syndrome
Acta Obstet Gynecol Scand
Low-dose gonadotropin therapy in polycystic ovary syndrome
Ann NY Acad Sci
Hormonal profiles following clomiphene citrate therapy in conception and nonconception cycles
Clin Endocrinol (Oxf)
A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome
J Clin Endocrinol Metab
Cited by (43)
Review of current guidelines for recurrent pregnancy loss: new strategies for optimal evaluation of women who may be superfertile
2019, Seminars in PerinatologyCitation Excerpt :An increased risk of pregnancy loss is associated with abnormal glucose levels. Accordingly, it is important to correct any abnormal levels of fasting blood glucose and/or hemoglobin A1C (HgbA1c) in the preconception period to reduce the risks as recommended by ASRM.32 Patients with polycystic ovary syndrome (PCOS) are also at higher risk of miscarriage, however assessment of fasting blood sugar and insulin in this setting, is yet not recommended.33,34
Classic and Cutting-Edge Strategies for the Management of Early Pregnancy Loss
2014, Obstetrics and Gynecology Clinics of North AmericaCitation Excerpt :Patients with poorly controlled diabetes are known to have an increased risk of spontaneous miscarriage, which is reduced to normal spontaneous loss rates when women are euglycemic preconceptually.32 Testing for fasting insulin and glucose is simple, and treatment with insulin-sensitizing agents can reduce the risk of recurrent miscarriage.33 More recently, determining the average load of blood glucose through testing of hemoglobin A1C has become an increasingly used modality to evaluate insulin resistance.1
Recurrent pregnancy loss
2006, Clinical GynecologyUse of Metformin for Ovulation Induction in Women Who Have Polycystic Ovary Syndrome With or Without Evidence of Insulin Resistance
2006, Journal of Obstetrics and Gynaecology CanadaPredictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: Obese, lean, hyper or normoinsulinemic?
2005, European Journal of Obstetrics and Gynecology and Reproductive BiologyMetformin treatment of PCOS during adolescence and the reproductive period
2005, European Journal of Obstetrics and Gynecology and Reproductive Biology